{
    "id": 26863,
    "fullName": "FGF4 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FGF4 amplification indicates an increased number of copies of the FGF4 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2249,
        "geneSymbol": "FGF4",
        "terms": [
            "FGF4",
            "FGF-4",
            "HBGF-4",
            "HST",
            "HST-1",
            "HSTF-1",
            "HSTF1",
            "K-FGF",
            "KFGF"
        ]
    },
    "variant": "amp",
    "createDate": "08/11/2017",
    "updateDate": "08/11/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11671,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of FGF3, FGF4, and FGF19 was associated with acquired resistance to combination treatment with Herceptin (trastuzumab) and Tykerb (lapatinib) in an ERBB2 (HER2)-amplified breast cancer cell line xenograft model (PMID: 28381415).",
            "molecularProfile": {
                "id": 28184,
                "profileName": "ERBB2 amp FGF19 amp FGF3 amp FGF4 amp"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9699,
                    "pubMedId": 28381415,
                    "title": "HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28381415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16228,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, FGF3, FGF4, and FGF19 were coamplified in 90% (8/9) of FGFR1-amplified tumors in patients with ER-positive, ERBB2 (HER2)-negative breast cancer, and the coamplification was associated with resistance to Femara (letrozole) treatment (p=0.0001) (PMID: 28751448).",
            "molecularProfile": {
                "id": 31564,
                "profileName": "ESR1 pos FGF19 amp FGF3 amp FGF4 amp FGFR1 amp"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20155,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in an objective response rate (ORR) of 0% (0/18) and a clinical benefit rate of 11% (2/18) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring 11q13 (containing FGF3, FGF4, FGF19, and CCND1) amplification but not FGFR1 amplification, 11q13 amplification was associated with poor response (7%, 2/29) in biomarker analysis (PMID: 31619444; NCT02053636).",
            "molecularProfile": {
                "id": 34910,
                "profileName": "CCND1 amp FGF19 amp FGF3 amp FGF4 amp"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17719,
                    "pubMedId": 31619444,
                    "title": "Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31619444"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28183,
            "profileName": "FGF4 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28184,
            "profileName": "ERBB2 amp FGF19 amp FGF3 amp FGF4 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31564,
            "profileName": "ESR1 pos FGF19 amp FGF3 amp FGF4 amp FGFR1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34910,
            "profileName": "CCND1 amp FGF19 amp FGF3 amp FGF4 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}